SPONTAN Real-World Study Reports 93% Response
Filed with ASX · · 5 pages · English
Summary by 6ix AI
LTR Pharma Limited reports outcomes from a real-world study of its SPONTAN treatment, highlighting a significant response rate among men seeking convenience in erectile dysfunction therapy. These findings suggest that SPONTAN may serve as an effective alternative for men who have not responded well to traditional oral therapies. LTR Pharma plans to present this data at an upcoming conference and is preparing for further clinical investigations and U.S. commercialization of its products.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from LTR Pharma
- LTR Executes U.S. Commercial Agreement with Strive
- LTR Executes Definitive U.S. Commercial Agreement with Shed
- Response to ASX Aware Letter
- LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
- LTR Secures First U.S. Commercial Agreement for ROXUS
Later from LTR Pharma
- FY26 Results Announcement
- SPONTAN Phase II Final Results
- First ROXUS Prescriptions Fulfilled in the United States
- Australian-Developed ED Nasal Spray Now Being Prescribed in the U.S.
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow LTR Pharma into a list and get an email when it puts out news.
Follow LTR Pharma